ZA921270B - Peptides for treatment - Google Patents

Peptides for treatment

Info

Publication number
ZA921270B
ZA921270B ZA921270A ZA921270A ZA921270B ZA 921270 B ZA921270 B ZA 921270B ZA 921270 A ZA921270 A ZA 921270A ZA 921270 A ZA921270 A ZA 921270A ZA 921270 B ZA921270 B ZA 921270B
Authority
ZA
South Africa
Prior art keywords
absent
thr
ser
gly
cys
Prior art date
Application number
ZA921270A
Other languages
English (en)
Inventor
Ove Pedersen
Pedersen Ove
D K Macfadden
K Macfadden D
Original Assignee
Carlbiotech Ltd As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlbiotech Ltd As filed Critical Carlbiotech Ltd As
Publication of ZA921270B publication Critical patent/ZA921270B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA921270A 1991-02-25 1992-02-21 Peptides for treatment ZA921270B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK031991A DK31991D0 (da) 1991-02-25 1991-02-25 Peptid og farmaceutisk praeparat indeholdende et saadant peptid

Publications (1)

Publication Number Publication Date
ZA921270B true ZA921270B (en) 1992-11-25

Family

ID=8092219

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA921270A ZA921270B (en) 1991-02-25 1992-02-21 Peptides for treatment

Country Status (13)

Country Link
US (1) US5763406A (fr)
EP (1) EP0573538B1 (fr)
JP (1) JP3250804B2 (fr)
AT (1) ATE118349T1 (fr)
AU (1) AU1377092A (fr)
CA (1) CA2101075C (fr)
DE (1) DE69201438T2 (fr)
DK (2) DK31991D0 (fr)
ES (1) ES2070635T3 (fr)
GR (1) GR3015888T3 (fr)
IE (1) IE69853B1 (fr)
WO (1) WO1992014751A1 (fr)
ZA (1) ZA921270B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5593967A (en) * 1990-08-31 1997-01-14 Warner-Lambert Company Cholecystokinin antagonists, their preparation and therapeutic use
AU697847B2 (en) * 1993-09-24 1998-10-15 Advanced Immunit, Inc. Method for the treatment or prevention of eczema/dermatitis
DE4345062A1 (de) * 1993-12-31 1995-07-13 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von Viruserkrankungen
US6458766B1 (en) * 1998-12-15 2002-10-01 The Regents Of The University Of California Halovir, an antiviral marine natural product, and derivatives thereof
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
US7374068B2 (en) * 2004-10-08 2008-05-20 Homax Products, Inc. Particulate materials for acoustic texture material
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
EP3519427A4 (fr) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Méthodes et compositions pour le traitement d'herpès
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
PL448078A1 (pl) * 2024-03-22 2025-09-29 Uniwersytet Jagielloński Koniugat do stosowania w profilaktyce i leczeniu infekcji wywoływanych przez wirusa opryszczki pospolitej typu pierwszego

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190127A1 (fr) * 1984-08-10 1986-08-13 MERCK PATENT GmbH Agents polypeptides immunotherapeutiques
US4585587A (en) * 1984-10-19 1986-04-29 Northwestern University Antigenic peptide compounds
IT1190433B (it) * 1985-12-11 1988-02-16 Prodotti Antibiotici Spa Peptidi correlati al lisozima
AU7544987A (en) * 1986-06-03 1988-01-11 Pert, C.B. Small peptides which inhibit binding to t-4 receptors
EP0249394B1 (fr) * 1986-06-03 1993-10-27 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Petits peptides qui inhibent la liaison avec les récepteurs T-4 et agissent comme immunogènes
WO1988009338A1 (fr) * 1987-05-22 1988-12-01 Syntbiotech, Inc. Peptides synthetiques et procede de traitement du sida
ATE168698T1 (de) * 1988-05-27 1998-08-15 Us Health Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides

Also Published As

Publication number Publication date
IE920496A1 (en) 1992-08-26
DK31991D0 (da) 1991-02-25
DE69201438T2 (de) 1995-10-05
WO1992014751A1 (fr) 1992-09-03
GR3015888T3 (en) 1995-07-31
ATE118349T1 (de) 1995-03-15
EP0573538A1 (fr) 1993-12-15
JPH06507386A (ja) 1994-08-25
EP0573538B1 (fr) 1995-02-15
DK0573538T3 (da) 1995-06-26
CA2101075A1 (fr) 1992-08-26
DE69201438D1 (en) 1995-03-23
IE69853B1 (en) 1996-10-02
AU1377092A (en) 1992-09-15
JP3250804B2 (ja) 2002-01-28
US5763406A (en) 1998-06-09
ES2070635T3 (es) 1995-06-01
CA2101075C (fr) 2003-04-22

Similar Documents

Publication Publication Date Title
GR3015888T3 (en) Peptides for treatment.
AU6819294A (en) Oral drug delivery compositions and methods
NZ502872A (en) Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
MD1652F2 (en) Protein possessing the cytokin - type activity, recombinant DNA-codifyer for such protein, transformed cells and microorganism, expression vector, process for protein obtaining and remedy containing such a protein
ATE162201T1 (de) Cnp-gen und vorläuferprotein aus schwein
HU9401989D0 (en) A novel human kunitz-type protease inhibitor and variants thereof
CA2002924A1 (fr) Antithrombines
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
YU29596A (sh) Genski proizvodi koji regulišu gojaznost
CA2025070A1 (fr) Procede de genie genetique mettant en oeuvre des alleles de l'aprotinine recombinants pour la preparation a l'aide de microorganismes d'alleles de l'aprotinine traites de facon homogene et leur utilisation en therapeutique
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
CA2102606A1 (fr) Compositions pour le traitement du syndrome de fatigue chronique
CA2196308A1 (fr) Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin
DE3751398D1 (de) Substrat-Peptide.
CA2102447A1 (fr) Cyclopeptides
AU6354298A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
EP0613375A4 (fr) Compositions polypetidiques pharmaceutiques contenant de la lysine et procedes d'utilisation desdites compositions.
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
ATE92078T1 (de) Pharmakologisch aktive peptide.
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
CA2216704A1 (fr) Nouveaux peptides et medicaments pour les maladies osseuses contenant ces peptides comme ingredient actif
DE60038310D1 (de) Menschliche antithrombin-varianten
ATE106088T1 (de) Peptide und deren verwendung in der therapie.
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция